Skip to main content
Full access
Letter to the Editor
Published Online: 1 July 1999

Risperidone Monotherapy for Mania and Depression

Publication: American Journal of Psychiatry
To the Editor: Recently, risperidone (alone or, mostly, in combination with other mood stabilizers) has been tried in the treatment of bipolar disorder (1, 2). Nevertheless, its effects on mood seem hardly predictable: it has antimanic effects in some patients (1, 2) but mania-inducing (or antidepressant) effects in others (2). We describe a patient with bipolar disorder in whom risperidone monotherapy exhibited marked efficacy for his sequential manic and depressive states.
Mr. A, a 27-year-old man of Chinese descent, was physically healthy and did not abuse substances. About 1 year ago, he was hospitalized for his first episode of DSM-IV psychotic mania. Elevated moods, lessened need for sleep, hyperactivity, pressured speech, flight of ideas, grandiosity, and visual, mood-congruent hallucinations significantly impaired various areas of functioning. Physical examinations, laboratory tests, drug screening, chest X-rays, an ECG, and an EEG all produced negative results. In addition, his elder brother was also a victim of bipolar disorder. Mr. A and his father gave written informed consent for him to receive risperidone monotherapy; his dose was titrated to 3 mg b.i.d. over 3 days. Both psychotic and mood symptoms vanished within 3 weeks; he was then transferred to our outpatient department with the same drug regimen.
Two weeks later, Mr. A abruptly discontinued his medication because of a lack of full insight; after 6 days, a less severe manic state (without psychotic features) returned. Five days later, risperidone alone (3 mg b.i.d.) was reinstituted, abating his mood turmoil over 1 week. Unfortunately, 1 month later, he again discontinued his medication; a DSM-IV major depressive episode with melancholic features ensued 1 week later. Distinct depressed moods, significant anorexia, early morning awakening, loss of energy, marked psychomotor retardation, loss of pleasure in all activities, excessive guilt, and feelings of hopelessness caused drastic distress. After another 2 weeks, the same monotherapy alleviated the depressive state within 1 week. Three weeks later, Mr. A halted the medicine for a third time. Thereafter, he was free of psychotic and mood symptoms for 9 months, until another major depressive episode (with similar symptoms) developed. Two weeks later, the earlier treatment strategy curtailed this episode over 1 week. No adverse drug reaction ever emerged; no other medication, even as an adjunct, was coadministered throughout.
To our knowledge, this is the first report of risperidone monotherapy for both manic and depressive episodes of bipolar disorder. Although Mr. A’s mood fluctuation might merely reflect the natural course of his illness, the temporal relationship with risperidone’s (re)initiation or suspension suggests otherwise. Rigorous studies are needed to examine this preliminary observation.

References

1.
Freeman MP, Stoll AL: Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155:12–21
2.
Lane HY, Lin YC, Chang WH: Mania induced by risperidone: dose related? (letter). J Clin Psychiatry 1998; 59:85–86

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1115
PubMed: 10401466

History

Published online: 1 July 1999
Published in print: July 1999

Authors

Affiliations

WEN-HO CHANG, M.D.
Taipei, Taiwan

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share